Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Updates in Surgery
Published in: Updates in Surgery 1/2021

01-02-2021 | Anal Cancer | Consensus Conference

Hellenic society of medical oncology (HESMO) guidelines for the management of anal cancer

Authors: Nikolaos Gouvas, Sophia Gourtsoyianni, Maria Angeliki Kalogeridi, John Sougklakos, Louisa Vini, Evangelos Xynos, the Hellenic Society of Medical Oncology (HESMO)

Published in: Updates in Surgery | Issue 1/2021

Login to get access

Abstract

Despite considerable improvement in the management of anal cancer, there is a great deal of variation in the outcomes among European countries, and in particular among different hospital centres in Greece and Cyprus. The aim was to elaborate a consensus on the multidisciplinary management of anal cancer, based on European guidelines (European Society of Medical Oncologists-ESMO), considering local special characteristics of our healthcare system. Following discussion and online communication among members of an executive team, a consensus was developed. Guidelines are proposed along with algorithms of diagnosis and treatment. The importance of centralisation, care by a multidisciplinary team (MDT) and adherence to guidelines are emphasised.
Literature
1.
2.
Wilkinson JR, Morris EJ, Downing A et al (2014) The rising incidence of anal cancer in England 1990–2010: a population-based study. Colorectal Dis 16:234CrossRef
3.
Glynne-Jones R, Nilsson PJ, Aschele C et al (2014) Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii10-20PubMedCrossRef
4.
Amini A, Jones BL, Ghosh D, Schefter TE, Goodman KA (2017) Impact of facility volume on outcomes in patients with squamous cell carcinoma of the anal canal: analysis of the national cancer data base. Cancer 123:228–236PubMedCrossRef
5.
Schmoll HJ, Van Cutsem E, Stein A et al (2012) ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 23:2479–2516PubMedCrossRef
6.
Ackley BJ, Swan BA, Ladwig G, Tucker S (2008) Evidence-based nursing care guidelines: medical-surgical interventions. Mosby Elsevier, St Louis
7.
Geh I, Gollins S, Renehan A et al (2017) Association of Coloproctology of Great Britain & Ireland (ACPGBI): guidelines for the management of cancer of the colon, rectum and anus (2017)—Anal Cancer. Colorectal Dis 19(Suppl 1):82–97PubMedCrossRef
8.
Abramowitz L, Jacquard AC, Jaroud F et al (2011) Human papillomavirus genotype distribution in anal cancer in France: the EDiTH V study. Int J Cancer 129:433–439PubMedCrossRef
9.
Valmary-Degano S, Jacquin E, Pretet JL et al (2013) Signature patterns of human papillomavirus type 16 in invasive anal carcinoma. Hum Pathol 44:992–1002PubMedCrossRef
10.
Piketty C, Selinger-Leneman H, Bouvier AM et al (2012) Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the french hospital database on HIV. J Clin Oncol 30:4360–4366PubMedCrossRef
11.
Frisch M, Biggar RJ, Goedert JJ (2000) Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 92:1500–1510PubMedCrossRef
12.
Moureau-Zabotto L, Vendrely V, Abramowitz L et al (2017) Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP). Dig Liver Dis 49:831–840PubMedCrossRef
13.
Bosman FT, World Health Organization and International Agency for Research on Cancer (2010)WHO classification of tumours of the digestive system. International Agency for Research on Cancer, Lyon.
14.
15.
16.
Darragh TM, Colgan TJ, Cox JT et al (2012) The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med 136:1266–1297PubMedCrossRef
17.
Edge SB, American Joint Committee on Cancer (2010) AJCC cancer staging manual. Springer, New York
18.
Roach SC, Hulse PA, Moulding FJ, Wilson R, Carrington BM (2005) Magnetic resonance imaging of anal cancer. Clin Radiol 60:1111–1119PubMedCrossRef
19.
Kochhar R, Plumb AA, Carrington BM, Saunders M (2012) Imaging of anal carcinoma. AJR Am J Roentgenol 199:335CrossRef
20.
Gourtsoyianni S, Goh V (2014) MRI of anal cancer: assessing response to definitive chemoradiotherapy. Abdom Imaging 39:2–17PubMedCrossRef
21.
Otto SD, Lee L, Buhr HJ, Frericks B, Hocht S, Kroesen AJ (2009) Staging anal cancer: prospective comparison of transanal endoscopic ultrasound and magnetic resonance imaging. J Gastrointest Surg 13:1292–1298PubMedCrossRef
22.
Prezzi D, Mandegaran R, Gourtsoyianni S et al (2018) The impact of MRI sequence on tumour staging and gross tumour volume delineation in squamous cell carcinoma of the anal canal. Eur Radiol 28:1512–1519PubMedCrossRef
23.
Koh DM, Dzik-Jurasz A, O’Neill B, Tait D, Husband JE, Brown G (2008) Pelvic phased-array MR imaging of anal carcinoma before and after chemoradiation. Br J Radiol 81:91–98PubMedCrossRef
24.
Goh V, Gollub FK, Liaw J et al (2010) Magnetic resonance imaging assessment of squamous cell carcinoma of the anal canal before and after chemoradiation: can MRI predict for eventual clinical outcome? Int J Radiat Oncol Biol Phys 78:715–721PubMedCrossRef
25.
Kochhar R, Renehan AG, Mullan D, Chakrabarty B, Saunders MP, Carrington BM (2017) The assessment of local response using magnetic resonance imaging at 3- and 6-month post chemoradiotherapy in patients with anal cancer. Eur Radiol 27:607–617PubMedCrossRef
26.
Glynne-Jones R, Sebag-Montefiore D, Meadows HM et al (2017) Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial. Lancet Oncol 18:347–356PubMedPubMedCentralCrossRef
27.
28.
Balachandra B, Marcus V, Jass JR (2007) Poorly differentiated tumours of the anal canal: a diagnostic strategy for the surgical pathologist. Histopathology 50:163–174PubMedCrossRef
29.
Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471–1474.
30.
Ryan R, Gibbons D, Hyland JM et al (2005) Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 47:141–146PubMedCrossRef
31.
Nigro ND, Vaitkevicius VK, Considine B (1974) Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum 17:354–356PubMedCrossRef
32.
33.
Deshmukh AA, Zhao H, Das P et al (2018) Clinical and economic evaluation of treatment strategies for T1N0 anal canal cancer. Am J Clin Oncol 41:626–631PubMedPubMedCentralCrossRef
34.
Chai CY, Tran Cao HS, Awad S, Massarweh NN (2018) Management of stage I squamous cell carcinoma of the anal canal. JAMA Surg 153:209–215PubMedCrossRef
35.
Alfa-Wali M, Dalla Pria A, Nelson M, Tekkis P, Bower M (2016) Surgical excision alone for stage T1 anal verge cancers in people living with HIV. Eur J Surg Oncol 42:813–816PubMedCrossRef
36.
Flam M, John M, Pajak TF et al (1996) Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 14:2527–2539PubMedCrossRef
37.
Gunderson LL, Winter KA, Ajani JA et al (2012) Long-term update of US GI intergroup RTOG 98–11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol 30:4344–4351PubMedPubMedCentralCrossRef
38.
Kachnic LA, Tsai HK, Coen JJ et al (2012) Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. Int J Radiat Oncol Biol Phys 82:153–158PubMedCrossRef
39.
Salama JK, Mell LK, Schomas DA et al (2007) Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol 25:4581–4586PubMedCrossRef
40.
Chuong MD, Freilich JM, Hoffe SE et al (2013) Intensity-modulated radiation therapy vs. 3D conformal radiation therapy for squamous cell carcinoma of the anal canal. Gastrointest Cancer Res 6:39–45PubMedPubMedCentral
41.
Glynne-Jones R, Meadows HM, Lopes A, et al (2020) Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus: results of a post hoc analysis from the randomised phase III ACT II trial. Ann Oncol .
42.
Anonymous (1996) Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 348:1049–1054CrossRef
43.
Bartelink H, Roelofsen F, Eschwege F et al (1997) Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 15:2040–2049PubMedCrossRef
44.
Faivre C, Rougier P, Ducreux M et al (1999) 5-Fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer. Bull Cancer 86:861–865PubMed
45.
Evesque L, Benezery K, Follana P et al (2017) Multimodal therapy of squamous cell carcinoma of the anus with distant metastasis: a single-institution experience. Dis Colon Rectum 60:785–791PubMedCrossRef
46.
Rao S, Sclafani F, Eng C et al (2020) International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAAct. J Clin Oncol 38:2510–2518PubMedCrossRefPubMedCentral
47.
Kim S, Jary M, Mansi L et al (2013) DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma. Ann Oncol 24:3045–3050PubMedCrossRef
48.
Kim S, Francois E, Andre T et al (2018) Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. Lancet Oncol 19:1094–1106PubMedCrossRef
49.
Grifaichi F, Padovani A, Romeo F, Trinca C, Moscetti L, Cortesi E (2001) Response of metastatic epidermoid anal cancer to single agent irinotecan: a case report. Tumori 87:58–59PubMedCrossRef
50.
Abbas A, Nehme E, Fakih M (2011) Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy. Anticancer Res 31:4637–4640PubMed
51.
Saif MW, Kontny E, Syrigos KN, Shahrokni A (2011) The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series. J Oncol 2011:125467PubMedPubMedCentralCrossRef
52.
Morris VK, Salem ME, Nimeiri H et al (2017) Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol 18:446–453PubMedPubMedCentralCrossRef
53.
Ott PA, Piha-Paul SA, Munster P et al (2017) Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol 28:1036–1041PubMedPubMedCentralCrossRef
54.
55.
Graham BD, Jetmore AB, Foote JE, Arnold LK (2005) Topical 5-fluorouracil in the management of extensive anal Bowen’s disease: a preferred approach. Dis Colon Rectum 48:444–450PubMedCrossRef
56.
Richel O, de Vries HJ, van Noesel CJ, Dijkgraaf MG, Prins JM (2013) Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial. Lancet Oncol 14:346–353PubMedCrossRef
57.
Scholefield JH, Harris D, Radcliffe A (2011) Guidelines for management of anal intraepithelial neoplasia. Colorectal Dis 13(Suppl 1):3–10PubMedCrossRef
58.
Stier EA, Goldstone SE, Berry JM et al (2008) Infrared coagulator treatment of high-grade anal dysplasia in HIV-infected individuals: an AIDS malignancy consortium pilot study. J Acquir Immune Defic Syndr 47:56–61PubMedCrossRef
59.
Chiao EY, Giordano TP, Richardson P, El-Serag HB (2008) Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era. J Clin Oncol 26:474–479PubMedCrossRef
60.
Lim F, Glynne-Jones R (2011) Chemotherapy/chemoradiation in anal cancer: a systematic review. Cancer Treat Rev 37:520–532PubMedCrossRef
61.
Oette M, Mosthaf FA, Sautter-Bihl ML, Esser S (2017) HIV-associated anal dysplasia and anal carcinoma. Oncol Res Treat 40:100–105PubMedCrossRef
62.
Sparano JA, Lee JY, Palefsky J et al (2017) Cetuximab plus chemoradiotherapy for HIV-associated anal carcinoma: a phase II AIDS malignancy consortium trial. J Clin Oncol 35:727–733PubMedCrossRef
63.
Palefsky JM (2015) Screening to prevent anal cancer: current thinking and future directions. Cancer Cytopathol 123:509–510PubMedCrossRef
64.
Fox PA, Seet JE, Stebbing J et al (2005) The value of anal cytology and human papillomavirus typing in the detection of anal intraepithelial neoplasia: a review of cases from an anoscopy clinic. Sex Transm Infect 81:142–146PubMedPubMedCentralCrossRef
65.
Crawshaw BP, Russ AJ, Stein SL et al (2015) High-resolution anoscopy or expectant management for anal intraepithelial neoplasia for the prevention of anal cancer: is there really a difference? Dis Colon Rectum 58:53–59PubMedCrossRef
66.
Wieland U, Kreuter A (2018) The importance of HPV16 in anal cancer prevention. Lancet Infect Dis 18:131–132PubMedCrossRef
67.
Ortholan C, Resbeut M, Hannoun-Levi JM et al (2012) Anal canal cancer: management of inguinal nodes and benefit of prophylactic inguinal irradiation (CORS-03 Study). Int J Radiat Oncol Biol Phys 82:1988–1995PubMedCrossRef
68.
Ben-Josef E, Moughan J, Ajani JA et al (2010) Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87–04 and 98–11. J Clin Oncol 28:5061–5066PubMedPubMedCentralCrossRef
69.
Kachnic LA, Winter K, Myerson RJ et al (2013) RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 86:27–33PubMedCrossRef
70.
Moureau-Zabotto L, Ortholan C, Hannoun-Levi JM et al (2013) Role of brachytherapy in the boost management of anal carcinoma with node involvement (CORS-03 study). Int J Radiat Oncol Biol Phys 85:135CrossRef
71.
Papillon J, Montbarbon JF, Gerard JP, Chassard JL, Ardiet JM (1989) Interstitial curietherapy in the conservative treatment of anal and rectal cancers. Int J Radiat Oncol Biol Phys 17:1161–1169PubMedCrossRef
72.
73.
Frakulli R, Buwenge M, Cammelli S et al (2018) Brachytherapy boost after chemoradiation in anal cancer: a systematic review. J Contemp Brachytherapy 10:246–253PubMedPubMedCentralCrossRef
74.
Ajani JA, Winter KA, Gunderson LL et al (2008) Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 299:1914–1921PubMedCrossRef
75.
James RD, Glynne-Jones R, Meadows HM et al (2013) Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial. Lancet Oncol 14:516–524PubMedCrossRef
76.
Matzinger O, Roelofsen F, Mineur L et al (2009) Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011–40014). Eur J Cancer 45:2782–2791PubMedCrossRef
77.
Sebag-Montefiore D, Meadows HM, Cunningham D et al (2012) Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin. Radiother Oncol 104:155–160PubMedCrossRef
78.
Glynne-Jones R, Meadows H, Wan S et al (2008) EXTRA–a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. Int J Radiat Oncol Biol Phys 72:119–126PubMedCrossRef
79.
Meulendijks D, Dewit L, Tomasoa NB et al (2014) Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. Br J Cancer 111:1726–1733PubMedPubMedCentralCrossRef
80.
Oliveira SC, Moniz CM, Riechelmann R et al (2016) Phase II study of capecitabine in substitution of 5-FU in the chemoradiotherapy regimen for patients with localized squamous cell carcinoma of the anal canal. J Gastrointest Cancer 47:75–81PubMedCrossRef
81.
Deutsch E, Lemanski C, Pignon JP et al (2013) Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial. Ann Oncol 24:2834–2838PubMedCrossRef
82.
83.
Cooper R, Mason M, Finan P, Byrne P, Sebag-Montefiore D (2012) Defunctioning stomas prior to chemoradiation for anal cancer are usually permanent. Colorectal Dis 14:87–91PubMedCrossRef
Metadata
Title
Hellenic society of medical oncology (HESMO) guidelines for the management of anal cancer
Authors
Nikolaos Gouvas
Sophia Gourtsoyianni
Maria Angeliki Kalogeridi
John Sougklakos
Louisa Vini
Evangelos Xynos
the Hellenic Society of Medical Oncology (HESMO)
Publication date
01-02-2021
Publisher
Springer International Publishing
Published in
Updates in Surgery / Issue 1/2021
Print ISSN: 2038-131X
Electronic ISSN: 2038-3312
DOI
https://doi.org/10.1007/s13304-020-00923-2

Other articles of this Issue 1/2021

Updates in Surgery 1/2021 Go to the issue

Original Article

Enhanced recovery after surgery in colon and rectal surgery: identification of predictive variables of failure in a monocentric series including 733 patients

Original Article

Implementation of intracorporeal anastomosis in laparoscopic right colectomy is safe and associated with a shorter hospital stay

Original Article

A comparative cost analysis of transanal and laparoscopic total mesorectal excision for rectal cancer

Original Article

Colorectal surgery during the COVID-19 outbreak: do we need to change?

Review Article

Predictors of bowel necrosis in patients with acute mesenteric ischemia: systematic review and meta-analysis

Original Article

One-year evaluation of anorectal functionality and quality of life in patients affected by mid-to-low rectal cancer treated with transanal total mesorectal excision